Moexipril

From WikiMD's Wellness Encyclopedia

Information about Moexipril[edit source]

Moexipril is an angiotensin-converting enzyme (ACE) inhibitor which is used in the therapy of hypertension. Moexipril is associated with a low rate of transient serum aminotransferase elevations, but has yet to be linked to instances of acute liver injury.

Moexipril

Mechanism of action of Moexipril[edit source]

Moexipril (moe ex' i pril) is an ACE inhibitor which is approved for use alone and in combination with other agents in the therapy of hypertension. Like other ACE inhibitors, moexipril inhibits the conversion of angiotensin I, a relatively inactive molecule, to angiotensin II which is the major mediator of vasoconstriction and volume expansion induced by the renin-angiotensin system. Other host enzymes besides that which converts angiotensin I to II may be inhibited as well, which may account for some of the side effects of the ACE inhibitors.

FDA approval information for Moexipril[edit source]

Moexipril was approved for use in the United States in 1991 and is available in 7.5 and 15 mg tablets in several generic forms and under the trade name Univasc.

Dosage and administration for Moexipril[edit source]

The typical daily dose in adults is 7.5 to 30 mg in one or two divided doses which is administered long term. Moexipril is also available in fixed dose combinations with hydrochlorothiazide (Uniretic and generics).

Side effects of Moexipril[edit source]

Common side effects include dizziness, fatigue, headache, cough, gastrointestinal upset and skin rash. Common ACE inhibitors include the following:

Moexipril Resources

Contributors: Prab R. Tumpati, MD